LCM
ALLO icon

Lynx1 Capital Management’s Allogene Therapeutics ALLO Stock Holding History

Lynx1 Capital Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-546,119
Closed -$677K – 24
2025
Q3 		$677K Sell
546,119
-10,510,890
-95% -$12.5M 0.14% 13
2025
Q2 		$12.5M Hold
11,057,009
– – 3.61% 6
2025
Q1 		$16.1M Buy
11,057,009
+182,286
+2% +$344K 5.78% 6
2024
Q4 		$23.2M Buy
10,874,723
+4,672,349
+75% +$11.5M 8.68% 5
2024
Q3 		$17.4M Buy
6,202,374
+3,974,079
+178% +$10.6M 6.15% 6
2024
Q2 		$5.19M Buy
+2,228,295
New +$6.57M 1.87% 7

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $141B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
PSC
Patient Square Capital Menlo Park, California $564M AUM 261.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return